GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

UK's Cytospire draws in $83m for new T-cell engager platform

Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

CDR-Life Announces CDR209, a Novel T Cell Engager for Treatment of Axial Spondyloarthritis

Lucy Liu

Director, Protein Sciences WuXi Biologics

Thursday 10th December 2026

Optimizing T-Cell Engagers from Design to Development: Format Selection, Screening Strategies, and Translational Characterization

9:30 am

Optimize T-cell engager design and format selection to balance potency, safety, and developability
Accelerate candidate discovery through high-throughput screening and differentiated functional profiling
Translate promising candidates toward development through in vivo efficacy, PK characterization, and case studies